299 related articles for article (PubMed ID: 17303901)
1. Bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
[TBL] [Abstract][Full Text] [Related]
2. [Research on mechanism underlying bone damage in myeloma--review].
Zhou LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1340-4. PubMed ID: 18088497
[TBL] [Abstract][Full Text] [Related]
3. New insights into the pathophysiology and management of bone disease in multiple myeloma.
Terpos E; Politou M; Rahemtulla A
Br J Haematol; 2003 Dec; 123(5):758-69. PubMed ID: 14632767
[No Abstract] [Full Text] [Related]
4. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
[TBL] [Abstract][Full Text] [Related]
5. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
7. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
8. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
10. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
11. [Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease].
Feng Y; Tang WJ; Zou ZQ; Cui J; Zhang L; Niu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):686-692. PubMed ID: 36065703
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
13. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
14. New insights in myeloma-induced osteolysis.
Barillé-Nion S; Bataille R
Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
16. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
17. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases.
Sipos W; Pietschmann P; Rauner M
Curr Med Chem; 2008; 15(2):127-36. PubMed ID: 18220768
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Vengerovskiĭ AI; Khlusov IA; Nechaev KA
Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
[TBL] [Abstract][Full Text] [Related]
19. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
20. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]